One of the therapeutic approaches tried for OPA1-related mitochondrial diseases is genome editing using small ribonucleoprotein particle U1 (U1 snRNP), especially since 30% of OPA1 pathogenic variants are splice-site [99]. Here, OPA1 is linked to mitochondrial disease.